Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 15/20 | 0.78 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.78 |
| ▸ | RORC | P51449 | 7/20 | 0.77 |
| ▸ | RORA | P35398 | 3/20 | 0.77 |
| ▸ | RORB | Q92753 | 3/20 | 0.77 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.77 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | RXRA | P19793 | 1/20 | 0.77 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.77 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.77 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.77 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.77 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.77 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.77 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.77 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| T091317 SCHEMBL457231 | 0.87 | RORC (1.00) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL6032023 | 0.86 | NR1I2 (0.79) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL13651537 | 0.85 | NR1I2 (1.00) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL16063605 | 0.82 | RORC (0.86) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL12334077 | 0.74 | RORC (0.81) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL14732110 | 0.74 | RORC (1.00) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL5623558 | 0.73 | ESR1 (0.72) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL18235558 | 0.73 | HSD11B1 (1.00) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL16731518 | 0.73 | RORC (0.81) | NR1I2NR1H2RORCRORARORB | |
| SCHEMBL14732184 | 0.73 | RORC (0.77) | NR1I2NR1H2RORCRORARORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010023317-A1 | NOVEL HEXAFLUORO-2-BIPHENYLISOPROPANOL COMPOUNDS THAT MODULATE LXR-TYPE RECEPTORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS IN HUMAN AND VETERINARY MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | disclosed |
| EP-1599447-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076418-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | NR1H2, NR1H3, RXRG | NR1I2 10/4885NR1H2 1/4885RORC 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.